Literature DB >> 28406320

Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway.

Odd Martin Vallersnes1,2, Per Sverre Persett3, Elisabeth Leere Øiestad4,5, Ritva Karinen4, Fridtjof Heyerdahl6, Knut Erik Hovda6.   

Abstract

CONTEXT: Recreational drug toxicity is frequent. Availability of new psychoactive substances is steadily increasing. However, data with verified analyses from clinical settings are limited. To evaluate the impact of novel psychoactive substances (NPS) on recreational drug toxicity in Oslo, Norway, we analysed samples from a selection of patients.
METHODS: All the patients presenting with recreational drug toxicity at the Oslo Accident and Emergency Outpatient Clinic (OAEOC) and at the Oslo University Hospital (OUH) were registered from April through September 2014. Oral fluid samples were collected at the OAEOC. Blood samples were collected at the OUH. The samples were screened using ultra-high performance liquid chromatography - tandem mass spectrometry (UHPLC-MS/MS).
RESULTS: Nine hundred and sixty-four cases were included, 841 (87.2%) at the OAEOC and 123 (12.8%) at the OUH. A total of 55 oral fluid samples (OAEOC) and 103 blood samples (OUH) could be analysed. NPS were not clinically suspected in any of the screened cases. At the outpatient clinic, the most commonly found substances were clonazepam in 42/55 (76.4%) cases, amfetamines in 40/55 (72.7%) and heroin in 39/55 (70.9%). In seven (12.7%) cases NPS were detected: 4-methylamfetamine in three cases, dimethyltryptamine in two, methylone in one, and N,N-dimethyl-3,4-methylenedioxyamfetamine in one. Among the hospital patients, the most commonly found substances were clonazepam in 51/103 (49.5%) cases, amfetamines in 48/103 (46.6%), heroin in 31/103 (30.1%), and diazepam in 30/103 (29.1%). In five (4.9%) cases NPS were detected: JWH-210 in two cases, AM-2201 in two, and 5-EAPB in one.
CONCLUSION: NPS were clinically not suspected, though found in eight percent of cases. Still, the vast majority of patients treated for recreational drug toxicity in Oslo have taken classical drugs. Management of these patients should be based on their clinical condition. However, it is highly important to be alert to atypical presentations possibly resulting from unsuspected drugs.

Entities:  

Keywords:  Poisoning; laboratory confirmation; novel psychoactive substances; overdose; recreational drugs

Mesh:

Substances:

Year:  2017        PMID: 28406320     DOI: 10.1080/15563650.2017.1312002

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  5 in total

1.  Acute poisoning related to the recreational use of prescription drugs: an observational study from Oslo, Norway.

Authors:  Marit Mæhle Grimsrud; Mette Brekke; Victoria Lykke Syse; Odd Martin Vallersnes
Journal:  BMC Emerg Med       Date:  2019-10-15

2.  Unspecified opioids among opioid overdoses in Oslo, Norway.

Authors:  Zahra Zeineb Iqbal; Thanh Mai Thi Nguyen; Mette Brekke; Odd Martin Vallersnes
Journal:  BMC Res Notes       Date:  2022-04-09

3.  Poisoning with central stimulant drugs: an observational study from Oslo, Norway.

Authors:  Erlend Ingebrigtsen; Per Sverre Persett; Mette Brekke; Fridtjof Heyerdahl; Knut Erik Hovda; Odd Martin Vallersnes
Journal:  Int J Emerg Med       Date:  2022-09-29

4.  Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues.

Authors:  Stefania Bonaccorso; Antonio Metastasio; Angelo Ricciardi; Neil Stewart; Leila Jamal; Naasir-Ud-Dinn Rujully; Christos Theleritis; Stefano Ferracuti; Giuseppe Ducci; Fabrizio Schifano
Journal:  Brain Sci       Date:  2018-07-14

5.  The Swiss Prison Study (SWIPS): Protocol for Establishing a Public Health Registry of Prisoners in Switzerland.

Authors:  Thomas Gaisl; Naser Musli; Patrick Baumgartner; Marc Meier; Silvana K Rampini; Eva Blozik; Edouard Battegay; Malcolm Kohler; Shekhar Saxena
Journal:  JMIR Res Protoc       Date:  2020-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.